These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22541978)

  • 1. [Daptomycin in outpatient antimicrobial parenteral therapy].
    Cervera C; Mestres CA
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():59-63. PubMed ID: 22541978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.
    Nathwani D
    J Antimicrob Chemother; 2009 Sep; 64(3):447-53. PubMed ID: 19584105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial).
    Cervera C; Sanroma P; González-Ramallo V; García de la María C; Sanclemente G; Sopena N; Pajarón M; Segado A; Mirón M; Antón F; Basterretxea A; Cuende A; Miró JM;
    Infect Dis (Lond); 2017 Mar; 49(3):200-207. PubMed ID: 27820968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure].
    Sarriá Cepeda C
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():38-42. PubMed ID: 22541974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience.
    Seaton RA; Gonzalez-Ramallo VJ; Prisco V; Marcano-Lozada M; Gonzalez-Ruiz A; Gallegos B; Menichetti F; Loeffler J; Bouylout K; Chaves RL
    Int J Antimicrob Agents; 2013 May; 41(5):468-72. PubMed ID: 23473943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
    Rybak MJ
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
    Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ
    Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The EUCORE registry: objectives and general results].
    Cercenado E; Pachón J
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():3-9. PubMed ID: 22541969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient parenteral antibiotic therapy: principles and practice.
    Seaton RA; Barr DA
    Eur J Intern Med; 2013 Oct; 24(7):617-23. PubMed ID: 23602223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Daptomycin in home hospitalization].
    González Ramallo VJ
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():48-54. PubMed ID: 21477704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
    Mathiesen L; Midtvedt T; Solberg CO
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci.
    Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM
    Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient parenteral antimicrobial therapy: Recent developments and future prospects.
    Török ME; Chapman AL; Lessing MP; Sanderson F; Seaton RA
    Curr Opin Investig Drugs; 2010 Aug; 11(8):929-39. PubMed ID: 20721835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.